okt 17, 2018: 2 p.m. - 2:55 p.m.
The Hong Kong Stock Exchange is capturing worldwide attention as it modifies listing rules to permit biotech companies, opening the door for Chinese firms seeking public market financing as well international firms eyeing the support of investors in China. In just the exchange%u2019s first few weeks more than USD 1 billion in new offerings have generated funding that will be applied to accelerate clinical research on behalf of patients. This session will examine cross-border perspectives on the appetite of China-based investors for biotechs and the criteria to determine the attractiveness of listing on the exchange for foreign entities as Hong Kong sets its sights at becoming a major biotech funding source.%uFFFD
Moderator: Joshua Berlin, Executive Director & Editor of New Ventures, BioCentury%uFFFD